RNAZ
Transcode Therapeutics Inc
NASDAQ: RNAZ · HEALTHCARE · BIOTECHNOLOGY
$8.01
-4.64% today
Updated 2026-04-30
Market cap
$7.75M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-52.59
Dividend yield
—
52W range
$6 – $22
Volume
0.0M
Transcode Therapeutics Inc (RNAZ) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-46.30%
ROA
-14.10%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | — | $-453440.00 | — | — | — |
| 2019 | $0.00 | $-607212.00 | — | — | — |
| 2020 | $0.00 | $-2.34M | — | — | — |
| 2021 | $0.00 | $-6.84M | — | — | — |
| 2022 | $0.00 | $-17.56M | — | — | — |
| 2023 | $0.00 | $-18.55M | — | — | — |
| 2024 | $0.00 | $-16.75M | — | — | — |
| 2025 | $0.00 | $-34.66M | — | — | — |